X
BBIO icon

Xponance’s BridgeBio Pharma BBIO Stock Holding History

Xponance’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Buy
27,099
+11,771
+77% +$824K 0.01% 589
2026
Q1 		$1.14M Buy
15,328
+2,792
+22% +$202K 0.01% 704
2025
Q4 		$959K Buy
12,536
+272
+2% +$17.9K 0.01% 704
2025
Q3 		$637K Sell
12,264
-148
-1% -$7.22K 0.01% 879
2025
Q2 		$536K Buy
12,412
+1,938
+19% +$70.5K ﹤0.01% 922
2025
Q1 		$362K Buy
10,474
+385
+4% +$13K ﹤0.01% 1032
2024
Q4 		$277K Buy
10,089
+844
+9% +$21.8K ﹤0.01% 1157
2024
Q3 		$235K Buy
9,245
+374
+4% +$9.82K ﹤0.01% 1170
2024
Q2 		$225K Buy
8,871
+1,803
+26% +$49.3K ﹤0.01% 1144
2024
Q1 		$219K Buy
7,068
+106
+2% +$3.6K ﹤0.01% 1161
2023
Q4 		$281K Buy
+6,962
New +$209K ﹤0.01% 1073
2021
Q4 		– Sell
-5,053
Closed -$237K – 1175
2021
Q3 		$237K Sell
5,053
-840
-14% -$45K ﹤0.01% 1091
2021
Q2 		$359K Buy
+5,893
New +$337K 0.01% 1024

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Xponance's BBIO Position: Q2 2026 in Review

Xponance increased its BridgeBio Pharma (BBIO) stake by 77% in Q2 2026, buying an estimated $824K and bringing the position to 27,099 shares worth $2.02M. The position accounts for 0.01% of the portfolio, ranked #589.

Xponance first reported a position in BBIO in Q2 2021 and has held it in 13 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Xponance held 27,099 shares of BridgeBio Pharma worth $2.02M as of Q2 2026.
  • Xponance bought 11,771 BridgeBio Pharma shares in Q2 2026, an estimated $824K.
  • BridgeBio Pharma made up 0.01% of Xponance's portfolio in Q2 2026, its #589 holding.
  • Xponance first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 13 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.